NOVOSEVEN® RT

NovoSeven® RT

FDA INDICATION: Treatment of bleeding episodes in hemophilia A or B with inhibitors and in acquired hemophilia. Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B with inhibitors and in acquired hemophilia. Treatment of bleeding episodes in congenital FVII deficiency. Package Insert

CLASS: Recombinant

DISTRIBUTOR: Novo Nordisk

VIAL SIZE: 1, 2, 5, 8 mg

DILUENT SIZE: 1.1, 2.1, 5.2, 8.1 mL

MIXING DEVICE: MixPro™

ROOM TEMPERATURE STORAGE: Until product expiration

DURATION OF BYPASS ACTIVITY: Approximately 2 hours

OTHER WEBSITES: mynovosecure.comnovosevenrt.com